Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Seeks 19.8 Billion Yen for Launch of Pandemic Agency JIHS in April
August 30, 2024
- MHLW Requests Funds for Adding PMDA Reviewers, Subsidizing Advisory Fees in FY2025
August 29, 2024
- MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
- MHLW’s Tax Reform Request Not Yet Clear, HSC Debate Might Be a Cue
August 29, 2024
- LDP Health Division OKs MHLW’s FY2025 Budget Request
August 29, 2024
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- Trintellix, Vtama Get 2-Year Extension of Re-Examination Period
August 29, 2024
- Japan Doles Out Orphan Tags for 10 APIs, Pulls Status for Biogen’s MS Drug
August 29, 2024
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
- Panel Conditionally OKs Change to Allow Use of Abortion Pill at Clinics Without Beds
August 28, 2024
- Japan Panel Clears Amgen’s TED Med, Rexulti for Alzheimer’s Agitation and More
August 28, 2024
- High-Dose Mecobalamin Now in Line to Become Japan’s 1st ALS Med in 9-Plus Years
August 28, 2024
- MHLW Sets Global Health Vision to Enhance Drug Innovation Ecosystem
August 28, 2024
- Sakigake Tags Granted to GSK’s Bepirovirsen, Boehringer’s Nerandomilast
August 28, 2024
- MHLW to Address Drug Loss, Generic Industry Reform in FY2025 Budget Request
August 26, 2024
- Astellas Pharma Employee Indicted in China
August 23, 2024
- New LDP Study Group Seeks Budget to Bolster Immunoglobulin Production
August 23, 2024
- BMS’ ROS1 Inhibitor, Janssen’s Bispecific Up for Review on Aug. 30
August 20, 2024
- Kobayashi Declares Bid for LDP Race, Urges More Investment in Pharma
August 20, 2024
- MHLW to Present Detailed Criteria for Exclusion from “Specified Clinical Trials”
August 20, 2024
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…